Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.9500
+0.0032 (0.34%)
At close: May 12, 2025, 4:00 PM
0.9212
-0.0288 (-3.03%)
After-hours: May 12, 2025, 6:49 PM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Opus Genetics stock have an average target of 7.00, with a low estimate of 6.00 and a high estimate of 8.00. The average target predicts an increase of 636.84% from the current stock price of 0.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 11, 2025.
Analyst Ratings
The average analyst rating for Opus Genetics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +531.58% | Apr 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
13.41M
from 10.99M
Increased by 22.00%
Revenue Next Year
26.94M
from 13.41M
Increased by 100.89%
EPS This Year
-0.91
from -2.15
EPS Next Year
-0.52
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.2M | 31.5M | 41.3M | ||
| Avg | 13.4M | 26.9M | 24.4M | ||
| Low | 9.8M | 21.7M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 65.3% | 134.9% | 53.2% | ||
| Avg | 22.0% | 100.9% | -9.3% | ||
| Low | -10.8% | 61.7% | -63.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.84 | -0.42 | -0.55 | ||
| Avg | -0.91 | -0.52 | -0.60 | ||
| Low | -1.07 | -0.72 | -0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.